Find similar products:
The text only version may be available in large print, Braille or audio CD. For further information call emc accessibility on 0800 198 5000. The product code(s) for this leaflet is: PL 53095/0009.
VARIVAX
VARIVAX® powder and solvent for suspension for injection in a pre-filled syringe
Varicella Vaccine (live)
1. What VARIVAX is and what it is used for
2. What you need to know before you or your child receives VARIVAX
3. How VARIVAX is given
4. Possible side effects
5. How to store VARIVAX
6. Contents of the pack and other information
VARIVAX is a vaccine to help protect adults and children against chickenpox (varicella). Vaccines are used to protect you or your child against infectious diseases.
VARIVAX can be administered to persons 12 months of age or older.
VARIVAX may also be administered to infants from 9 months of age under special circumstances, such as to conform with national vaccination schedules or in outbreak situations.
It may also be given to persons who have no history of chickenpox, but who have been exposed to someone who has chickenpox.
Vaccination within 3 days of exposure may help prevent chickenpox or reduce the severity of disease, resulting in fewer skin lesions and shorter duration of illness. In addition, there is limited information that being vaccinated up to 5 days after exposure may reduce disease severity.
As with other vaccines, VARIVAX does not completely protect all individuals from naturally acquired chickenpox.
In rare circumstances, it is possible to catch chickenpox, including severe chickenpox, from a person who has been vaccinated with VARIVAX. This may occur in persons who have not previously been vaccinated or have not had chickenpox, as well as persons who fall into one of the following categories:
Whenever possible, individuals who have been vaccinated with VARIVAX should attempt to avoid close contact, for up to 6 weeks following the vaccination, with anyone who falls into one of the categories above. Tell your doctor if there is anyone who falls into one of the categories above and is expected to be in close contact with the person being vaccinated.
Talk to your doctor or pharmacist before you or your child receive VARIVAX:
Tell your doctor or pharmacist if you or your child are taking or have recently taken any other medicines (or other vaccines).
If any type of vaccine is due to be given at the same time as VARIVAX, your doctor or health care professional will advise you whether this can be given or not. VARIVAX may be given at the same time as the following routine childhood vaccinations: measles, mumps and rubella vaccine (MMR), vaccines against Haemophilus influenza type b, hepatitis B, diphtheria, tetanus, pertussis (whooping cough) and polio vaccine that is given by mouth.
Vaccination should be deferred for at least 5 months after any blood or plasma transfusions, or administration of normal human immune globulin (a sterile solution of naturally produced antibodies taken from donated human blood) or varicella zoster immune globulin (VZIG) have been given.
Following vaccination with VARIVAX, you or your child should not receive any immune globulin, including VZIG, for 1 month thereafter unless your doctor decides it is necessary.
Vaccine recipients should avoid products that contain aspirin (salicylates) for 6 weeks after vaccination with VARIVAX as this may cause a serious condition called Reye syndrome which can affect all your body organs.
VARIVAX should not be administered to pregnant women.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before the vaccination is given. Also, it is important that you do not become pregnant within one month after having the vaccine. During this time you should use an effective method of birth control to avoid pregnancy.
Inform your doctor if you are breast-feeding or if you intend to breast-feed. Your doctor will decide if you should receive VARIVAX.
There is no information to suggest that VARIVAX will affect your ability to drive or use machines.
This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially ‘sodium-free’.
This medicine contains less than 1 mmol potassium (39 mg) per dose, that is to say essentially ‘potassium-free’.
VARIVAX will be administered by your doctor or health care professional.
VARIVAX is given by injection as follows:
The number and timing of doses should be determined by your doctor, using the official recommendations.
VARIVAX should not be given to children under 9 months of age.
VARIVAX should be injected into the muscle or under the skin either in the area of the outer thigh or of the upper arm. Usually for injections into the muscle, the thigh area is preferred in young children, whereas for older individuals, the upper arm area is the preferred injection site.
If you have a blood clotting disorder or low levels of platelets in your blood, the injection will be given under the skin.
Your doctor or health care professional will take care that VARIVAX is not injected into the bloodstream.
Overdose is very unlikely because the vaccine is provided in single dose vials and is given by a doctor or health care professional.
Contact your doctor who will decide if a dose is required and when to give it.
Like all vaccines and medicines, this vaccine can cause side effects, although not everybody gets them.
Very rarely (reported in less than 1 in 10,000 people), a severe allergic reaction may occur with symptoms that may include facial swelling, low blood pressure, and difficulty breathing, with or without rash. These reactions often occur very soon after the injection. If any of these symptoms or other serious symptoms are noticed after vaccination, you must seek immediate medical attention.
Tell your doctor if you notice any of the following rare or very rare side effects:
The following side effects have been observed:
Very common reactions (reported by more than 1 out of 10 people) were:
Common reactions (reported by less than 1 out of 10 but more than 1 out of 100 people) were:
Uncommon reactions (reported by less than 1 out of 100 but more than 1 out of 1,000 people) were:
Rare reactions (reported by less than 1 out of 1,000 people but more than 1 out of 10,000 people) were:
Side effects that have been reported during marketed use of VARIVAX include:
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this vaccine out of sight and reach of children.
Do not use this vaccine after the expiry date which is stated on the box after EXP.
The expiry date refers to the last day of that month.
Store and transport refrigerated (2 °C – 8 °C). Do not freeze. Keep the vial in the outer carton in order to protect from light.
After reconstitution, the vaccine should be used immediately. However, the in-use stability has been demonstrated for 30 minutes between +20 °C and +25 °C.
Do not throw away any vaccines via wastewater or household waste. Ask your pharmacist how to throw away vaccines you no longer use. These measures will help to protect the environment.
The active ingredient is: live attenuated varicella virus (Oka/Merck strain) (produced in MRC-5 human diploid cells).
Each 0.5 mL dose of reconstituted vaccine contains: a minimum of 1,350 PFU (plaque forming units) of varicella virus (Oka/Merck strain).
The other ingredients are:
Powder:
Sucrose, hydrolysed gelatin, urea, sodium chloride, monosodium L-glutamate, anhydrous disodium phosphate, potassium dihydrogen phosphate and potassium chloride.
Residual components in trace quantities: neomycin.
Solvent:
Water for injections
Pharmaceutical form: powder and solvent for suspension for injection
The vaccine consists of a white to off-white powder in a vial and a clear colourless liquid solvent in a pre-filled syringe. The product is available in packs of one or 10 doses.
The solvent provided is a pre-filled syringe of water for injections. The secondary packaging may also contain 2 separate needles.
Not all pack sizes may be marketed.
Holder of the Marketing Authorisation:
Manufacturer Responsible for Batch Release
This medicine is authorised in the Member States of the European Economic Area, in the United Kingdom (Northern Ireland) and Great Britain under the following names:
VARIVAX
België/Belgique/Belgien; България; Česká republika; Danmark; Deutschland; Eesti; Ελλάδα; España; France; Hrvatska; Ireland; Ísland; Italia; Kύπρος; Latvija; Lietuva; Luxembourg/Luxemburg; Magyarország; Malta; Norge; Österreich; Polska; Portugal; România; Slovenija; Slovenská republika; Suomi/Finland; Sverige; United Kingdom (Northern Ireland), Great Britain
PROVARIVAX
Nederland
This leaflet was last revised in December 2023.
© 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved
PIL.VVX.23.UK.8382.II-125.RCN025626